Caris Life Sciences has just announced that the University of Puerto Rico will be inducted into their Precision Oncology Alliance (POA), making UPR the 28th member. Powered by the molecular science company, the POA is a network of cancer centers working to improve standards of care and practices for the application of molecular profiling in cancer treatment.
UPR serves 85 percent of Puerto Rico’s cancer patients and participates in medical research, molecular science, and the development of new drugs and treatments. UPR consists of the UPR Hospital at Carolina, Ambulatory Clinic of UPR, Puerto Rico Medical Center in San Juan, and the Comprehensive Cancer Center UPR. The network serves tens of thousands of patients every year.
“In addition to providing care for more than 25,000 patients each year, UPR is a leader in clinical and scientific research with a tremendous depth and breadth of data and clinical trial experience,” says Vice Chairman of Caris Life Sciences, Brian J. Brille, per release. “We are delighted to welcome its team to the Precision Oncology Alliance. They will add new perspectives to the collaborative network and enhance our efforts to advance precision medicine.”
Partnering with other cancer centers and academic institutions, UPR will work to broaden patient access to precision cancer care, collaborate with other alliance members to publish data and advance clinical trials, validate Caris’ Next Generation Profiling offerings, and establish evidence-based standards for tumor profiling and molecular testing in oncology.
Additionally, UPR-affiliated hospitals will be able to prioritize therapeutic options and determine the most beneficial clinical trial opportunities for their patients through leveraging the comprehensive genomic and proteomic tumor profiling services made available through the Caris Molecular Intelligence platform.
UPR is enthusiastic about the partnership with Caris Life Sciences, says Chancellor of UPR Medical Sciences Campus, Dr. Segundo Rodriguez-Quilichini. “The University of Puerto Rico’s mission is to provide the best cancer care by integrating research with the best and more advanced treatment… We are excited to develop this partnership with Caris Life Sciences, which has distinguished itself as an innovative, leading molecular science company focused on delivering on the promise of precision medicine.”
The Precision Oncology Alliance is comprised of 28 academic, hospital, and community-based cancer institutions, including seven National Cancer Institute-designated Comprehensive Cancer Centers.
